Iovance's lifileucel shows 50% response rate in soft tissue sarcoma pilot trial
IOVA•Iovance Biotherapeutics said lifileucel showed a 50% response rate in a pilot trial for advanced soft tissue sarcomas, with all responses ongoing at the September 9, 2026, cutoff.
1. Pilot trial results
Iovance Biotherapeutics announced that lifileucel produced a 50% response rate in a pilot trial for advanced soft tissue sarcomas. Tumor shrinkage occurred in refractory undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, and all responses remained ongoing at the September 9, 2026, cutoff.
2. Next study
The safety profile was consistent with the lifileucel treatment regimen in other indications. The FDA granted lifileucel fast track designation for both cancers in the second quarter of 2026, and enrollment is underway in the SARATOGA registrational study to support potential approvals.
